34 related articles for article (PubMed ID: 19082262)
1. Matching Drug Prices to Their Clinical Benefit-The Final Frontier?
Wilson ECF; Yiu ZZN
JAMA Dermatol; 2024 Apr; 160(4):387-388. PubMed ID: 38381443
[No Abstract] [Full Text] [Related]
2. Medicines policy, access and use in Mexico: a systematic literature review 2000-2022.
Vargas López LC; Chávez Gallegos D; Blanco Borjas DM; Wirtz VJ
Drugs Context; 2024; 13():. PubMed ID: 38384930
[TBL] [Abstract][Full Text] [Related]
3. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Global Health; 2017 Aug; 13(1):53. PubMed ID: 28764738
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
5. Generics market in Greece: the pharmaceutical industry's beliefs.
Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
[TBL] [Abstract][Full Text] [Related]
6. Restrictions on the reimbursement policy with regard to retail marketing of medicinal products in Poland.
Zimmermann A
Acta Pol Pharm; 2013; 70(2):339-43. PubMed ID: 23614291
[TBL] [Abstract][Full Text] [Related]
7. Out-of-pocket costs to users: medicine options for hypertension.
Arredondo A
Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
[No Abstract] [Full Text] [Related]
8. [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation and Economic Development. 2007].
Moïse P; Docteur E
Salud Publica Mex; 2008; 50 Suppl 4():S504-10. PubMed ID: 19082262
[No Abstract] [Full Text] [Related]
9. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
Openshaw MS
Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical policies in Canada: another example of federal-provincial discord.
Anis AH
CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
